Teva Lawsuit Against Eli Lilly Over Forteo Generic Revived by Appeals Court

A U.S. federal appeals court has reinstated a lawsuit by Teva Pharmaceuticals against Eli Lilly, reviving a legal battle over an alleged breach of a settlement agreement concerning a generic version of the osteoporosis drug Forteo. The ruling on Monday by the 7th U.S. Circuit Court of Appeals in Chicago overturns a lower court's previous dismissal of the case.

The Core Allegation

The dispute centers on a 2018 settlement agreement that resolved an earlier patent lawsuit filed by Lilly against Teva. Under that deal, Teva was permitted to launch its generic version of Forteo as early as 2019, just before Lilly's patents were set to expire.

However, Teva alleges that Lilly violated this agreement after the U.S. Food and Drug Administration (FDA) granted Lilly an additional three years of market exclusivity for Forteo in 2020. This regulatory extension delayed Teva's entry into the market until December 2023. Teva filed its lawsuit in 2024, seeking damages for the delayed launch.

Court's Rationale and Path Forward

A U.S. District Judge had previously dismissed Teva's case, ruling that the settlement agreement was no longer in effect after Lilly's patents expired. The 7th Circuit's three-judge panel reversed this decision, finding that the agreement's text was ambiguous about when its obligations ended and that the dispute could not be resolved in Lilly's favor based on the complaint alone.

Ad

The case, *Teva Pharmaceuticals USA Inc v. Eli Lilly & Co, No. 25-2125*, has now been sent back to the Indiana federal court for further proceedings. Representatives for both companies did not immediately respond to requests for comment, according to the original report.

Market Context

This legal battle underscores the significant financial stakes involved in patent settlements and generic drug launches. Delays in generic competition can protect substantial revenue streams for brand-name pharmaceutical companies but can also impact healthcare costs and patient access to more affordable medicines.

For investors, the final outcome of the lawsuit could have material financial implications. A victory for Teva could result in a significant damages award for lost revenue, while a ruling in Lilly's favor would affirm its actions regarding Forteo's exclusivity.